Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691092 · ClinicalTrials.gov registry record · NA
PET Imaging of mGLuR5 With Drug Challenge
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 79
- Enrollment target
NCT01691092 is a NA study that has completed, run by Yale University. The registered enrollment target is 79 participants.
The verdict
NCT01691092, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 79 participants
- Enrollment target
Study Summary
This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans, and up to three Positron Emission Tomography (PET) scans, as well as cognitive testing at each scan session. For one of the PET scans, a drug (either ketamine or n-acetyl cysteine) will be administered. Hypothesis 1: The investigators hypothesize administration of ketamine or n-acetylcysteine (NAC) will lead to a decrease in mGluR5. Hypothesis 2: The investigators hypothesize an improvement in memory and attentional skills after drug challenge. Hypothesis 3: The investigators hypothesize an increase in mGluR5 availability and change in MRI measures post drug challenge as compared to baseline, signifying synaptogenesis. Hypothesis 4: We expect there should not be a significant difference in reduction in mGluR5 availability due to differences in ABP688 radiotracer infusion.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691092
The ClinicalTrials.gov registry entry for NCT01691092 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT01691092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691092 about?
NCT01691092 is a clinical study titled "PET Imaging of mGLuR5 With Drug Challenge". This study is designed to look at that involvement of a process in the brain called the glutamate system in depression. Participants will undergo a screening session, up to two functional Magnetic Resonance Imaging (fMRI) scans, and up to three Positron Emission Tomography (PET) scans, as well as co...
What is the current status of trial NCT01691092?
This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2012-06. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01691092?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT01691092?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.